FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 346:278-280 January 24, 2002 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Walsh, T. J. PubMed Citation

The risk of fungal infections increases greatly in patients with profound and protracted neutropenia. Because of the insensitivity of diagnostic methods and the poor outcomes associated with established infections, empirical antifungal therapy is used for patients with neutropenia who have persistent fever despite the administration of antibacterial agents. Although conventional amphotericin B has been considered the optimal first-line agent, its status as the preferred treatment has recently been challenged by the results of trials comparing it with antifungal triazoles and lipid formulations of amphotericin B (Table 1).

View this table: [in this window] [in a new window]   Table 1. Randomized Studies Comparing Treatment with Antifungal Agents for Fever during Neutropenia.

 
. . . [Full Text of this Article]

References

This article has been cited by other articles:

• Chen, C.-Y., Kumar, R. N., Feng, Y.-H., Ho, C.-H., You, J.-Y., Liao, C.-C., Tseng, C.-H., Mavros, P., Gerth, W. C., Chen, Y.-C. (2006). Treatment outcomes in patients receiving conventional amphotericin B therapy: a prospective multicentre study in Taiwan. J Antimicrob Chemother 57: 1181-1188 [Abstract] [Full Text]  
• Klastersky, J. (2004). Antifungal Therapy in Patients with Fever and Neutropenia -- More Rational and Less Empirical?. NEJM 351: 1445-1447 [Full Text]  
• Marty, F. M., Cosimi, L. A., Baden, L. R. (2004). Breakthrough Zygomycosis after Voriconazole Treatment in Recipients of Hematopoietic Stem-Cell Transplants. NEJM 350: 950-952 [Full Text]  
• Johnson, J. R., Ullmann, A. J., Heussel, C. P., Cornely, O. A., Apisarnthanarak, A., Little, J. R., Tebas, P., Walsh, T. J., Pappas, P. G., Winston, D. J. (2002). Voriconazole versus Liposomal Amphotericin B for Empirical Antifungal Therapy. NEJM 346: 1745-1747 [Full Text]  
• Walsh, T. J., Lee, J., Dismukes, W. E., Powers, J. H., Dixon, C. A., Goldberger, M. (2002). Decisions about Voriconazole versus Liposomal Amphotericin B. NEJM 346: 1499-1499 [Full Text]  
• (2002). Voriconazole: An Effective Option in Patients with Neutropenia and Fever?. JWatch Infect. Diseases 2002: 2-2 [Full Text]